By Editorial Staff
Published: July 16, 2026
In the ongoing debate over the skyrocketing cost of healthcare in the United States, prescription drug prices have long served as the primary lightning rod for public outrage and political reform. From the high-profile negotiations surrounding insulin to the landmark provisions of the Inflation Reduction Act, pharmaceutical costs have captured the nation’s attention. Yet, a glaring disparity remains: while the public and policymakers obsess over the price of a pill, the single largest driver of health spending growth—the hospital sector—continues to operate with significantly less scrutiny.
In a recent analysis for JAMA Health Forum, Larry Levitt, Executive Vice President for Health Policy at KFF, highlights a critical disconnect in our healthcare narrative. Despite hospitals accounting for a staggering 40% of the growth in national health spending between 2022 and 2024, they remain shielded from the same level of political and public pressure applied to pharmaceutical companies.
The Main Facts: A Tale of Two Cost Drivers
The American healthcare system is the most expensive in the world, yet the mechanisms of its inflation are often misunderstood. While drug prices are indeed rising, they represent only a portion of the total cost burden. Hospitals, which provide inpatient and outpatient services, are the financial backbone of the medical economy, and their influence on insurance premiums and out-of-pocket costs is profound.
The core of the issue lies in the lack of transparency and the complexity of hospital pricing. Unlike retail drugs, where a price tag is often visible at the pharmacy counter, hospital billing is an opaque ecosystem of "chargemasters," negotiated rates with private insurers, and facility fees. Because most patients interact with hospitals through the filter of insurance—and because medical emergencies often preclude "comparison shopping"—hospitals have been able to leverage their market power to command higher prices without the immediate public backlash faced by drug manufacturers.
Chronology: How We Reached This Impasse
The evolution of hospital pricing in America is not a sudden phenomenon but a result of decades of market consolidation and shifting regulatory environments.
- The 2010s: The Rise of Consolidation: Throughout the last decade, a massive wave of hospital mergers and acquisitions reduced competition in many regional markets. As hospital systems grew into regional monopolies, their leverage over private insurance companies skyrocketed, allowing them to dictate higher reimbursement rates.
- 2019-2022: The Pandemic Disruption: The COVID-19 pandemic introduced extreme volatility into hospital finances. While federal relief funds provided a temporary buffer, the post-pandemic landscape saw hospitals facing labor shortages and rising supply costs, which they largely passed on to private insurers.
- 2023-2024: A Period of Rapid Growth: Recent data from KFF and other health policy organizations indicate that as the healthcare system stabilized, hospital prices accelerated faster than inflation, particularly for those with private health insurance.
- 2025-2026: The Transparency Push: Federal mandates requiring hospitals to publish their negotiated rates with insurers were intended to create a "retail-like" market. However, the data remains difficult for the average consumer to interpret, keeping the pressure on hospitals relatively low compared to the aggressive legislative targeting of the pharmaceutical industry.
Supporting Data: By the Numbers
To understand why the focus remains on drugs, one must look at the visibility of the data. KFF’s analysis provides a sobering look at where the money is actually going:
- The 40% Share: Between 2022 and 2024, hospitals were responsible for nearly 40% of the total growth in national health spending. This dwarfs the spending growth attributed to retail prescription drugs, which, while high-profile, account for a smaller overall percentage of total national health expenditures.
- Private Insurance Disparity: Since 2019, hospital prices for privately insured patients have risen significantly faster than those for Medicare beneficiaries. This suggests that hospitals are leveraging their market power against private insurers to offset lower reimbursement rates from government programs.
- The "Facility Fee" Factor: A growing trend in hospital systems is the acquisition of physician practices. Once a practice is owned by a hospital, it can begin charging "facility fees" for routine visits—services that were previously cheaper in a standalone doctor’s office. This shift is a quiet, yet massive, driver of cost inflation.
Why the Disparity in Perception?
Levitt and other experts point to several psychological and structural reasons why drug prices capture more headlines:
1. The Direct-to-Consumer Marketing Effect
Pharmaceutical companies spend billions on television and digital advertising, creating a direct relationship with the patient. When a patient sees a drug they need—or want—on a commercial, the price becomes a tangible barrier. Hospitals, conversely, are viewed as essential community assets. They are the places where people go in moments of crisis, not brands that one "shops" for in the traditional sense.
2. The Nature of the Transaction
Buying a drug is a discrete, frequent event. A patient walks to the pharmacy, sees the price, and experiences the "sticker shock" immediately. Hospital care is often episodic, complex, and shrouded in layers of insurance processing. By the time a patient receives their "Explanation of Benefits," the actual cost of the hospital service is often obscured by deductibles, copays, and out-of-network adjustments.
3. Political Targeting
Legislators find it easier to target drug companies because they are a concentrated, highly profitable, and often unpopular industry. Hospitals, however, are often the largest employers in a congressional district. Challenging them carries significant political risk for lawmakers, as it can be framed as an attack on local jobs and access to essential emergency services.
Official Responses and Policy Implications
The lack of scrutiny on hospitals has begun to catch the eye of federal regulators. The Centers for Medicare & Medicaid Services (CMS) has implemented price transparency rules, but compliance remains inconsistent.
- The Regulatory Stance: Officials argue that if data is accessible, market forces will naturally curb the most egregious price hikes. However, critics suggest that without true competition—which is impossible in areas where a single hospital system controls the market—transparency alone is a "paper tiger."
- Policy Proposals: Experts are increasingly discussing "site-neutral payments." This policy would mandate that the same service be paid at the same rate regardless of whether it is performed in a hospital or a private clinic. This would eliminate the incentive for hospitals to acquire independent practices simply to hike the price of routine procedures.
- Antitrust Action: The Federal Trade Commission (FTC) has signaled a renewed interest in hospital mergers. By blocking further consolidation, the government hopes to maintain enough competition to prevent regional monopolies from setting exorbitant prices.
The Road Ahead: Implications for the System
The implication of this silence is clear: if we continue to focus only on drug prices, we are ignoring the structural rot in the hospital sector that is doing the most damage to the affordability of private health insurance.
If healthcare costs are to be reigned in, the conversation must broaden. We must move beyond the "villain-of-the-month" approach to drug pricing and engage in a more nuanced discussion about hospital market power, the role of facility fees, and the necessity of site-neutral payment reforms.
For the American consumer, the stakes are high. As hospital prices continue to climb, they are inevitably reflected in higher premiums and reduced wages. Until the public and their elected officials demand the same transparency and accountability from the hospital sector as they do from the pharmaceutical industry, the "invisible giant" of hospital costs will continue to exert an outsized influence on the economic well-being of the nation.
The path to a more affordable system requires more than just legislation; it requires a fundamental shift in how we perceive the delivery of care. Hospitals are not just community anchors; they are businesses with immense market power. Recognizing that power—and acting to moderate it—is the next great challenge for American healthcare reform.
About the Author
